These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18022543)

  • 21. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.
    Katou F; Ohtani H; Watanabe Y; Nakayama T; Yoshie O; Hashimoto K
    Cancer Res; 2007 Dec; 67(23):11195-201. PubMed ID: 18056444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
    Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
    J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escape from immune- and nonimmune-mediated tumor surveillance.
    Malmberg KJ; Ljunggren HG
    Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New dimensions in tumor immunology: what does 3D culture reveal?
    Feder-Mengus C; Ghosh S; Reschner A; Martin I; Spagnoli GC
    Trends Mol Med; 2008 Aug; 14(8):333-40. PubMed ID: 18614399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tumor-induced immunosuppression].
    Paul S; Calmels B; Régulier E
    Ann Biol Clin (Paris); 2002; 60(2):143-52. PubMed ID: 11937439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.
    Campoli M; Ferrone S
    Tissue Antigens; 2008 Oct; 72(4):321-34. PubMed ID: 18700879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.
    Demotte N; Stroobant V; Courtoy PJ; Van Der Smissen P; Colau D; Luescher IF; Hivroz C; Nicaise J; Squifflet JL; Mourad M; Godelaine D; Boon T; van der Bruggen P
    Immunity; 2008 Mar; 28(3):414-24. PubMed ID: 18342010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
    Wang E; Selleri S; Marincola FM
    Clin Cancer Res; 2007 Dec; 13(24):7228-31. PubMed ID: 18094399
    [No Abstract]   [Full Text] [Related]  

  • 30. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance.
    Di Carlo E; D'Antuono T; Pompa P; Giuliani R; Rosini S; Stuppia L; Musiani P; Sorrentino C
    Clin Cancer Res; 2009 May; 15(9):2979-87. PubMed ID: 19366834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of human bid gene expression enhances survival of CD8+ T cells.
    Lei XY; Xu YM; Wang T; Xie QS; Jia LT; Wang LF; Jin BQ; Yan Z; Yao LB; Yang AG
    Immunol Lett; 2009 Jan; 122(1):30-6. PubMed ID: 19046991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor dormancy and immunoescape.
    Quesnel B
    APMIS; 2008; 116(7-8):685-94. PubMed ID: 18834412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.
    Carlsson B; Sadeghi A; Bengtsson M; Wagenius G; Tötterman TH
    J Immunother; 2008 Sep; 31(7):633-43. PubMed ID: 18600181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abulsamad K; Adams SL
    Clin Immunol; 2008 Aug; 128(2):205-18. PubMed ID: 18511346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uses of telomerase peptides in anti-tumor immune therapy.
    Li H; Katik I; Liu JP
    Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
    Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
    Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer and immune response: old and new evidence for future challenges.
    de la Cruz-Merino L; Grande-Pulido E; Albero-Tamarit A; Codes-Manuel de Villena ME
    Oncologist; 2008 Dec; 13(12):1246-54. PubMed ID: 19056856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
    Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
    Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.